Great post Mr-Gold! Allen Ebens joined PTX in 2020. He was one of the founding executives at Juno Therapeutics. These executives don't get involved to just bang test tubes together. They want to be involved in the next generation cancer buster and do serious due diligence on the pre-clinical and clinical data before making the switch. Juno acquired by Celgene in 2018 for 9 billion the and year before Kite Therapeutics was acquired by Gilead for 11.8 billion. (The executives from Kite joined Paul Hopper at CHM) Cross-promotion approved apparently. Despite both Kite and Juno drugs making huge developments in Car-t technologies and changing the lives of many. Both these companies have car-t drugs for just blood cancers, as SYC (PTX CEO for those new to PTX) explains in all the investor presos, these blood cancer drugs are first-generation Car-T products and blood cancers makeup only 10% of all cancers. PTX is creating the second generation multi-target car-t's. We have seen how easy these Car-t candidates are approved and progressed with low safety even deaths for example Amgen's Lumakras. PTX100 is in a great position to crack the solid tumor Car-T space by targeting multiple Ras cells. They also have PTX200 and omnicar (the intel chip for other companies Car-t for controlling post-infusion) Great opportunity to get in on the ground floor (yes still ground floor). I have taken a good position and will be holding on and topping up. GLTA
PTX Price at posting:
16.0¢ Sentiment: Buy Disclosure: Held
